Consistent with these findings, we found that DLGAP5 was upregulated in LUAD, positively associated with TP53 mutation, and negatively associated with KRAS and EGFR mutation, indicating the tumor oncogenic activity of DLGAP5 in relation to the lung cancer hallmark genes. The gene discussed is EGFR; the disease is lung cancer.